Teva Pharmaceutical Industries Limited (TEVA) Expected to Post Quarterly Sales of $5.63 Billion

Equities analysts expect that Teva Pharmaceutical Industries Limited (NYSE:TEVA) will announce $5.63 billion in sales for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Teva Pharmaceutical Industries Limited’s earnings, with the highest sales estimate coming in at $5.72 billion and the lowest estimate coming in at $5.58 billion. Teva Pharmaceutical Industries Limited posted sales of $5.56 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 1.3%. The firm is scheduled to issue its next quarterly earnings report before the market opens on Thursday, November 2nd.

According to Zacks, analysts expect that Teva Pharmaceutical Industries Limited will report full-year sales of $5.63 billion for the current fiscal year, with estimates ranging from $22.40 billion to $22.99 billion. For the next fiscal year, analysts anticipate that the business will report sales of $21.67 billion per share, with estimates ranging from $21.17 billion to $22.76 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Teva Pharmaceutical Industries Limited.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.25 earnings per share.

A number of analysts have recently commented on the company. Royal Bank Of Canada lowered their target price on Teva Pharmaceutical Industries Limited from $21.00 to $15.00 and set an “underperform” rating on the stock in a research note on Monday, September 18th. Wells Fargo & Company restated a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, October 5th. Credit Suisse Group set a $39.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Maxim Group restated a “hold” rating and issued a $15.50 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, September 14th. Finally, Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research note on Thursday, June 22nd. Five research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $27.63.

Large investors have recently bought and sold shares of the stock. San Francisco Sentry Investment Group CA acquired a new stake in shares of Teva Pharmaceutical Industries Limited in the second quarter valued at approximately $106,000. Kistler Tiffany Companies LLC increased its stake in Teva Pharmaceutical Industries Limited by 74.7% during the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after acquiring an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC acquired a new stake in Teva Pharmaceutical Industries Limited during the first quarter worth $123,000. Bronfman E.L. Rothschild L.P. increased its stake in Teva Pharmaceutical Industries Limited by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after acquiring an additional 94 shares during the last quarter. Finally, Sterling Investment Advisors Ltd. increased its stake in Teva Pharmaceutical Industries Limited by 2.6% during the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after acquiring an additional 100 shares during the last quarter. 56.75% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This story was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://sportsperspectives.com/2017/10/11/teva-pharmaceutical-industries-limited-teva-expected-to-post-quarterly-sales-of-5-63-billion.html.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 15.89 on Wednesday. Teva Pharmaceutical Industries Limited has a 12 month low of $15.22 and a 12 month high of $44.76. The firm has a 50-day moving average price of $16.83 and a 200 day moving average price of $26.44. The stock’s market capitalization is $16.14 billion.

The business also recently declared a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were issued a $0.085 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $0.34 annualized dividend and a dividend yield of 2.14%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -15.36%.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries Limited (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply